S&P Global Analysts Give Novartis AG (NOVN) a CHF 87 Price Target

S&P Global set a CHF 87 target price on Novartis AG (VTX:NOVN) in a research note released on Tuesday, October 24th. The firm currently has a neutral rating on the stock.

A number of other research firms have also recently issued reports on NOVN. Deutsche Bank AG set a CHF 81 price objective on Novartis AG and gave the company a neutral rating in a research report on Wednesday, July 19th. HSBC Holdings plc set a CHF 90 price objective on Novartis AG and gave the company a buy rating in a research report on Tuesday, September 19th. Baader Bank set a CHF 90 price objective on Novartis AG and gave the company a buy rating in a research report on Tuesday, October 24th. UBS AG set a CHF 76 price objective on Novartis AG and gave the company a neutral rating in a research report on Tuesday, July 18th. Finally, Sanford C. Bernstein set a CHF 94 price objective on Novartis AG and gave the company a buy rating in a research report on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of CHF 86.10.

Novartis AG (NOVN) traded down CHF 0.15 during mid-day trading on Tuesday, reaching CHF 81.65. The company’s stock had a trading volume of 3,540,000 shares, compared to its average volume of 4,030,000. Novartis AG has a 12-month low of CHF 67.80 and a 12-month high of CHF 85.40.

ILLEGAL ACTIVITY NOTICE: “S&P Global Analysts Give Novartis AG (NOVN) a CHF 87 Price Target” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://stocknewstimes.com/2017/11/11/sp-global-analysts-give-novartis-ag-novn-a-chf-87-price-target.html.

Novartis AG Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply